III.J.02. Vaccines for the Prevention of Malaria. By FY96, transition to advanced development a candidate blood stage Plasmodium falciparum vaccine to reduce incidence of severe clinical malaria by 70 percent. By FY97, transition a vaccine to prevent P. falciparum infection in 70 percent of immunized troops. By FY98, transition to advanced development a candidate blood stage Plasmodium vivax vaccine to protect 70 percent of immunized troops from vivax malaria.
Supports: Army Modernization Plan, Medical Annex OProject, Sustain, and Protect the Force. The Medical Threat Facing a Force Projection Army (1994). Food and Drug Administration regulatory requirements.
|STO Manager:||TSO:||TRADOC POC:|
|COL W. H. Bancroft||MAJ Mark Seymour||Herbert Russakoff|
|MRMC||SARD-TM||CSS Battle Lab|